Treatment of Complex Regional Pain Syndrome type I; A randomised, single-blind, placebo-controlled study with multiple rounds of S(+)-ketamine infusions.
Suspended
- Conditions
- Complex Regional Pain Syndrome type I (CRPS type I)Complex Regionaal Pijn Syndroom type I (CRPS type I)
- Registration Number
- NL-OMON21045
- Lead Sponsor
- eiden University Medical Center (LUMC), Department of Anesthesiology
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
1. CRPS type I diagnosis according to the IASP-criteria;
2. NRS spontaneous pain score of 5 or higher;
Exclusion Criteria
1. Patients who are not able to give informed consent;
2. Patients suffering from other syndromes/diseases interfering with pain ratings;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Pain scores (NRS)<br /><br>- Allocation scores patients, whether they received S(+)-ketamine or placebo.
- Secondary Outcome Measures
Name Time Method - Occurence of side effects<br /><br>- Presence of CRPS type I diagnosis after treatment.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie S(+)-ketamine's efficacy in CRPS type I pain modulation?
How does S(+)-ketamine compare to standard-of-care treatments for CRPS type I in clinical trials?
Are there specific biomarkers that predict response to S(+)-ketamine infusions in CRPS type I patients?
What are the potential adverse events associated with multiple S(+)-ketamine infusions in CRPS type I?
What combination therapies or alternative drugs show promise in treating CRPS type I alongside ketamine?